Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2020

	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	9,739		$	6,417			—			—		$	16,156
Grant income		747			—			—			—			747
Total		10,486			6,417			—			—			16,903

Operating costs and expenses:
Cost of revenues		9,133			3,345			—			—			12,478
Research and development		395			580		$	188			—			1,163
Selling, general and administrative		5,902			2,667			—		$	2,492			11,061
Legal and related expenses		52			—			—			1,873			1,925
Total operating costs and expenses		15,482			6,592			188			4,365			26,627

Operating loss		(4,996	)		(175	)		(188	)		(4,365	)		(9,724	)

Other income (expense):
Interest		(7	)		11			—			83			87
Other		1			4			—			130			135
Foreign exchange loss		—			(358	)		—			—			(358	)
Loss before income taxes	$	(5,002	)	$	(518	)	$	(188	)	$	(4,152	)	$	(9,860	)

Depreciation and amortization included above	$	373		$	278		$	—		$	66		$	717

Share-based compensation included in above:
Selling, general and administrative		21			14			—			172			207
Total	$	21		$	14		$	—		$	172		$	207

Capital expenditures	$	225		$	60		$	—		$	—		$	285

	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	11,751		$	7,911			—			—		$	19,662

Operating costs, expenses and legal settlements, net:
Cost of revenues		10,963			3,397			—			—			14,360
Research and development		31			527		$	223			—			781
Selling, general and administrative		5,960			2,923			—		$	2,037			10,920
Legal fee expense		35			16			—			206			257
Legal settlements, net		—			(28,925	)		—			—			(28,925	)
Total operating costs, expenses, and legal settlements, net		16,989			(22,062	)		223			2,243			(2,607	)

Operating income (loss)		(5,238	)		29,973			(223	)		(2,243	)		22,269

Other income (expense):
Interest		(18	)		19			—			257			258
Other		6			—			—			64			70
Foreign exchange loss		—			(332	)		—			—			(332	)
(Loss) income before income taxes	$	(5,250	)	$	29,660		$	(223	)	$	(1,922	)	$	22,265

Depreciation and amortization included above	$	440		$	340		$	—		$	58		$	838

Share-based compensation included in above:
Selling, general and administrative		40			24			—			135			199
Total	$	40		$	24		$	—		$	135		$	199

Capital expenditures	$	120		$	446		$	—		$	—		$	566

	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	35,032		$	20,715			—			—		$	55,747
Grant income		747			—			—			—			747
Total		35,779			20,715			—			—			56,494

Operating costs and expenses:
Cost of revenues		30,351			10,223			—			—			40,574
Research and development		1,118			1,599		$	565			—			3,282
Selling, general and administrative		18,012			7,954			—		$	6,927			32,893
Legal and related expenses		140			1			—			5,540			5,681
Total operating costs and expenses		49,621			19,777			565			12,467			82,430

Operating income (loss)		(13,842	)		938			(565	)		(12,467	)		(25,936	)

Other income (expense):
Interest		(29	)		45			—			479			495
Other		20			(1	)		—			315			334
Foreign exchange loss		—			(88	)		—			—			(88	)
Income (loss) before income taxes	$	(13,851	)	$	894		$	(565	)	$	(11,673	)	$	(25,195	)

Depreciation and amortization included above	$	1,174		$	781		$	—		$	196		$	2,151

Share-based compensation included in above:
Selling, general and administrative		88			58			—			582			728
Total	$	88		$	58		$	—		$	582		$	728

Capital expenditures	$	514		$	205		$	—		$	—		$	719

	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	38,048		$	22,201			—			—		$	60,249

Operating costs, expenses and legal settlements, net:
Cost of revenues		32,956			10,391			—			—			43,347
Research and development		31			1,645		$	668			—			2,344
Selling, general and administrative		18,220			8,828			—		$	6,339			33,387
Legal fee expense		109			24			—			2,567			2,700
Legal settlements, net		—			(28,925	)		—			—			(28,925	)
Total operating costs, expenses and legal settlements, net		51,316			(8,037	)		668			8,906			52,853

Operating income (loss)		(13,268	)		30,238			(668	)		(8,906	)		7,396

Other income (expense):
Interest		(51	)		49			—			761			759
Other		17			—			—			232			249
Foreign exchange loss (gain)		—			(530	)		—			—			(530	)
(Loss) income before income taxes	$	(13,302	)	$	29,757		$	(668	)	$	(7,913	)	$	7,874

Depreciation and amortization included above.	$	1,217		$	1,025		$	—		$	130		$	2,372

Share-based compensation included in above:
Selling, general and administrative		118			74			—			553			725
Total	$	118		$	74		$	—		$	553		$	725

Capital expenditures	$	883		$	524		$	—		$	6,147		$	7,554